192 related articles for article (PubMed ID: 23209030)
1. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.
Mao Y; Triantafillou G; Hertlein E; Towns W; Stefanovski M; Mo X; Jarjoura D; Phelps M; Marcucci G; Lee LJ; Goldenberg DM; Lee RJ; Byrd JC; Muthusamy N
Clin Cancer Res; 2013 Jan; 19(2):347-56. PubMed ID: 23209030
[TBL] [Abstract][Full Text] [Related]
2. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
Stein R; Smith MR; Chen S; Zalath M; Goldenberg DM
Clin Cancer Res; 2009 Apr; 15(8):2808-17. PubMed ID: 19351768
[TBL] [Abstract][Full Text] [Related]
3. CD74 interferes with the expression of fas receptor on the surface of lymphoma cells.
Berkova Z; Wang S; Ao X; Wise JF; Braun FK; Rezaeian AH; Sehgal L; Goldenberg DM; Samaniego F
J Exp Clin Cancer Res; 2014 Oct; 33(1):80. PubMed ID: 25304249
[TBL] [Abstract][Full Text] [Related]
4. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
Govindan SV; Cardillo TM; Sharkey RM; Tat F; Gold DV; Goldenberg DM
Mol Cancer Ther; 2013 Jun; 12(6):968-78. PubMed ID: 23427296
[TBL] [Abstract][Full Text] [Related]
5. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
Alinari L; Mahoney E; Patton J; Zhang X; Huynh L; Earl CT; Mani R; Mao Y; Yu B; Quinion C; Towns WH; Chen CS; Goldenberg DM; Blum KA; Byrd JC; Muthusamy N; Praetorius-Ibba M; Baiocchi RA
Blood; 2011 Dec; 118(26):6893-903. PubMed ID: 22042694
[TBL] [Abstract][Full Text] [Related]
6. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression.
Frölich D; Blassfeld D; Reiter K; Giesecke C; Daridon C; Mei HE; Burmester GR; Goldenberg DM; Salama A; Dörner T
Arthritis Res Ther; 2012 Mar; 14(2):R54. PubMed ID: 22404985
[TBL] [Abstract][Full Text] [Related]
7. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells.
Hertlein E; Triantafillou G; Sass EJ; Hessler JD; Zhang X; Jarjoura D; Lucas DM; Muthusamy N; Goldenberg DM; Lee RJ; Byrd JC
Blood; 2010 Oct; 116(14):2554-8. PubMed ID: 20574049
[TBL] [Abstract][Full Text] [Related]
8. Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
Chen X; Chang CH; Stein R; Cardillo TM; Gold DV; Goldenberg DM
Biol Blood Marrow Transplant; 2013 Jan; 19(1):28-39. PubMed ID: 23025988
[TBL] [Abstract][Full Text] [Related]
9. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.
Martin P; Furman RR; Rutherford S; Ruan J; Ely S; Greenberg J; Coleman M; Goldsmith SJ; Leonard JP
Leuk Lymphoma; 2015; 56(11):3065-70. PubMed ID: 25754579
[TBL] [Abstract][Full Text] [Related]
11. Milatuzumab - a promising new immunotherapeutic agent.
Berkova Z; Tao RH; Samaniego F
Expert Opin Investig Drugs; 2010 Jan; 19(1):141-9. PubMed ID: 19968579
[TBL] [Abstract][Full Text] [Related]
12. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
[TBL] [Abstract][Full Text] [Related]
13. CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
Stein R; Mattes MJ; Cardillo TM; Hansen HJ; Chang CH; Burton J; Govindan S; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5556s-5563s. PubMed ID: 17875789
[TBL] [Abstract][Full Text] [Related]
14. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
15. ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.
Mani R; Chiang CL; Frissora FW; Yan R; Mo X; Baskar S; Rader C; Klisovic R; Phelps MA; Chen CS; Lee RJ; Byrd JC; Baiocchi R; Lee LJ; Muthusamy N
Exp Hematol; 2015 Sep; 43(9):770-4.e2. PubMed ID: 25937048
[TBL] [Abstract][Full Text] [Related]
16. The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival.
Shachar I; Haran M
Leuk Lymphoma; 2011 Aug; 52(8):1446-54. PubMed ID: 21417823
[TBL] [Abstract][Full Text] [Related]
17. The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies.
Markovič T; Podgornik H; Avsec D; Nabergoj S; Mlinarič-Raščan I
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163524
[TBL] [Abstract][Full Text] [Related]
18. Targeted liposomal drug delivery systems for the treatment of B cell malignancies.
Mittal NK; Bhattacharjee H; Mandal B; Balabathula P; Thoma LA; Wood GC
J Drug Target; 2014 Jun; 22(5):372-86. PubMed ID: 24433007
[TBL] [Abstract][Full Text] [Related]
19. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
Sapra P; Moase EH; Ma J; Allen TM
Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990
[TBL] [Abstract][Full Text] [Related]
20. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
Pereira DS; Guevara CI; Jin L; Mbong N; Verlinsky A; Hsu SJ; Aviña H; Karki S; Abad JD; Yang P; Moon SJ; Malik F; Choi MY; An Z; Morrison K; Challita-Eid PM; Doñate F; Joseph IB; Kipps TJ; Dick JE; Stover DR
Mol Cancer Ther; 2015 Jul; 14(7):1650-60. PubMed ID: 25934707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]